Pharmacological profile of venlafaxine, a new antidepressant, given acutely

Polish Journal of Pharmacology

Volumn 50, Issue 2, 1998, Pages 107-115

  Rogóz, Zofia ^a   Dziedzicka Wasylewska, Marta ^a   Maj, Jerzy ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Behavioral antidepressant test; Mice; Rats; Venlafaxine

Indexed keywords

ANTIDEPRESSANT AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

AGGRESSION; ANIMAL EXPERIMENT; ANTICHOLINERGIC EFFECT; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; DRUG MECHANISM; HEAD TWITCH; HYPOTHERMIA; IMMOBILIZATION; LOCOMOTION; MALE; MOUSE; NONHUMAN; RAT; RECEPTOR AFFINITY; SEDATION; STEREOTYPY;

AGGRESSION; ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BEHAVIOR, ANIMAL; CYCLOHEXANOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEAD MOVEMENTS; HYPOTHERMIA; MALE; MICE; MOTOR ACTIVITY; RATS; RATS, WISTAR; STEREOTYPED BEHAVIOR;

EID: 0031778856     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Benkert O., Gründer G., Wetzel H.: Is there an advantage to venlafaxine in comparison with other antidepressants? Hum. Psychopharmacol. Clin. Exp., 1997, 12, 53-64.
2. Corne S. J., Pickering R. W., Warner B. T.: A method for assessing the effects of drugs on the central actions of 5-hydroxytryptamine. Brit. J. Pharmacol., 1963, 20, 106-120.
3. Cunningham L. A., Borison R. L., Carman J. S., Chouinard G., Crowder J. E., Diamond B. I., Fischer D. E., Hearst E.: A comparison of venlafaxine, trazodone, and placebo in major depression. J. Clin. Psychopharmacol., 1994, 14, 99-106.
4. Cusack B., Nelson A., Richelson E.: Binding of antidepressants to human brain receptors; focus on newer generation compounds. Psychopharmacology, 1994, 114, 559-565.
5. Danjou P., Hackett D.: Safety and tolerance profile of venlafaxine. J. Clin. Psychopharmacol., 1995, 10, Suppl. 2, 15-20.
6. Fabre L. F., Putman H. P.: An ascending single-dose telerance study of Wy-45,030, a bicyclic antidepressant, in healthy men. Curr. Ther. Res., 1987, 42, 901-909.
7. Guelfi J. D., White C., Hackett D., Guichoux J. Y., Magni G.: Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J. Clin. Psychiat., 1995, 56, 450-458.
8. Holliday S. M., Benfield P.: Venlafaxine. A review of its pharmacology and therapeutic potential in depression. Drugs, 1995, 49, 280-294.
9. Lloyd K., Mitchell P.: Preclinical evaluation of venlafaxine, a novel antidepressant drug, in behavioral models of antidepressant activity. 21st Annual Meeting of the American College of Neuropsychopharmacology, San Juan, 1992, 190.
10. Maj J., Mogilnicka E., Klimek V., Kordecka-Magiera A.: Chronic treatment with antidepressants: potentiation of clonidine-induced aggresion in mice via noradrenergic mechanism. J. Neural Transm., 1981, 52, 189-197.
11. Maj J., Pawlowski L., Wiszniowska G.: The effect of tricyclic antidepressants in apomorphine-induced hypothermia in the mouse. Pol. J. Pharmacol. Pharm., 1974, 26, 329-336.
12. Maj J., Rogóż Z., Skuza G.: 5-Hydroxytryptamine uptake inhibitors antagonize the antireserpine effects of noradrenaline uptake inhibitors. J. Pharm. Pharmacol., 1983, 35, 128-129.
13. Maj J., Rogóż Z., Skuza G.: The pharmacological profile of venlafaxine, a new antidepressant. Biol. Psychiat., 1997, 42, Suppl., 238S.
14. Maj J., Rogóż Z., Skuza G., Sowińska H.: The effect of selective inhibitors of noradrenaline and serotonin uptake on reserpine- and apomorphine-induced hypothermia in mice. Pol. J. Pharmacol. Pharm., 1983, 35, 49-57.
15. 2-adrenergic and cholinergic system in mice. Pol. J. Pharmacol. Pharm., 1989, 41, 313-319.
16. Moyer J. A., Muth E. A., Haskins J. T.: In vivo antidepressant profiles of the novel bicyclic compound Wy-45,030 and Wy-45,881. Soc. Neurosci., 1984, 10, 261, abstr. 76.12.
17. Muth E. A., Haskins J. T., Moyer J. A., Husbands G. E. M., Nielsen T, Sigg E. B.: Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem. Pharmacol., 1986, 35, 4493-4497.
18. Muth E. A., Moyer J. H., Haskins J. T., Andree T. H., Husbands G. E. M.: Biochemical, neurophysiological and behavioral effects of Wy-45,233 and other identified metabolites of the antidepressant venlafaxine. Drug Develop. Res., 1991, 23, 191-199.
19. Ozawa H., Miyauchi T., Sugawara K.: Potentiating effect of lithium chloride on aggressive behaviour induced in mice by nialamide plus L-DOPA and clonidine. Eur. J. Pharmacol., 1975, 34, 169-179.
20. Porsolt R. D., Anton G., Blavet N., Jalfre M.: Behavioral despair in rats, a new model sensitivity to antidepressant treatments. Eur. J. Pharmacol., 1978, 47, 379-391.
21. Porsolt R. D., Bertin A., Jalfre M.: Behavioral despair in mice; a primary screening test for antidepressants. Arch. Int. Pharmacodyn. Ther., 1977, 229, 327-336.
22. Puech A. J., Frances H., Simon P.: Imipramine antagonism of apomorphine-induced hypothermia; a non-dopaminergic interaction. Eur. J. Pharmacol., 1978, 47, 125-127.
23. Schweizer E., Feighner J., Mandos L., Rickels K.: Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J. Clin. Psychiat., 1994, 55, 104-108.
24. Shrivastova R. K., Cohn C., Crowder J., Davidson J., Dunner D., Feighner J., Kiev A., Patrick R.: Long-term safety and clinic acceptability of venlafaxine and imipramine in outpatients with major depression. J. Clin. Psychopharmacol., 1994, 14, 322-329.
25. von Moltke L. L., Duan S. X., Greenblatt D. J., Fogelman S. M., Schmider J., Harmatz J. S., Shader R. I.: Venlafaxine and metabolites are very weak inhibitors of human cytochrome P450-3A isoforms. Biol. Psychiat., 1997, 41, 377-380.